Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with endometriosis.

Phase 2

Takeda

Leuprolide
Relugolix